XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.18

-5.1%

Dec 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (15923)	8/3/2002 9:44:46 AM
From: Cacaito	Read Replies (2) of 17367

From one of the 2 different links: ..."Amevive lowers total lymphocyte counts, as well as cell counts for CD4+ (T helper cells) and CD8+ (cytotoxic T cells) cells below the lower limit of normal in anywhere from 30-60% of subjects on the drug. The most important thing to note, in our opinion, is that the associated T cell reduction found with Amevive does not appear to have any significant clinical impact on patients."... The reports were quite good, but this part I will check into. I doubt that 30% to 60% of subjects experienced reductions "below the lower limit of normal". Many experienced reductions, few "below the lower limit of normal". The NEJM article did comment that there was an inverse relationship in the drug action: lower lymphocytes = higher responses. In this report, there is a part that has been confusing to many: ...the "associated T cell reduction found with Amevive does not appear to have any significant clinical impact on patients."... This is talking about the lack of side effects with the Tcell reductions, not about the lack of clinically beneficial effects. Very good findings, thank you!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next